Catalent Completes $1.2-Billion Acquisition of Paragon Bioservices

By Emily Forster -

May 22, 2019

Catalent has completed its $1.2-billion acquisition of Paragon Bioservices, a contract provider of viral vector development and manufacturing services for gene therapies.

Paragon has development and manufacturing capabilities in adeno-associated virus vectors, the most commonly used vector to delivery DNA to cells.

Paragon recently opened a new commercial manufacturing center near the Baltimore–Washington International Airport, equipped with 500-liter and 2,000-liter single-use bioreactors for clinical through commercial material production. The large-scale production campus, in addition to an expected second building built out for commercial GMP manufacturing, will be able to provide more than 425,000 square feet of manufacturing space upon completion.

Catalent says it will continue the resource dedication for Paragon’s customers and maintain a development and manufacturing partnership for its clients. Paragon currently employs over 380 staff members at its two Baltimore-area sites, all of whom are expected to join the 11,000 members of the Catalent team.

Source: Catalent